Crohn's disease: innate immunodeficiency? - PubMed
- ️Sun Jan 01 2006
Review
Crohn's disease: innate immunodeficiency?
Jesus-K Yamamoto-Furusho et al. World J Gastroenterol. 2006.
Abstract
In the past, Crohn's disease (CD) has been understood primarily as an immunologic disorder characterized by an abnormal T-cell response. Recent in vitro and in vivo data suggests that CD may instead be precipitated by innate immune dysfunction resulting from a combination of genetic and environmental factors. Some reports have demonstrated a defective immune response in a variety of other cellular components, including neutrophils, monocytes and dendritic cells. Recent studies of granulocyte-macrophage colony-stimulating factor (GM-CSF) in CD, aiming to stimulate the innate immune system with the conception that an innate immune defect underlies the development of the disease, have been demonstrated a clinical benefit and reinforce this evolving understanding of the disease.
Figures

Impairment of different innate immune mechanisms. These mechanisms play a central role in the homeostasis of intestinal barrier function. Identified environmental risks and genetic susceptibility may contribute to the innate immune dysfunction.

Targets of immunostimulation therapy in Crohn’s disease. Potential therapies encompass interventions focused on augmenting the intestinal innate immune function in different mechanisms of action.
Similar articles
-
Däbritz J. Däbritz J. Am J Physiol Gastrointest Liver Physiol. 2014 Mar;306(6):G455-65. doi: 10.1152/ajpgi.00409.2013. Epub 2014 Feb 6. Am J Physiol Gastrointest Liver Physiol. 2014. PMID: 24503766 Review.
-
Innate immunity in Crohn's disease: the reverse side of the medal.
Dessein R, Chamaillard M, Danese S. Dessein R, et al. J Clin Gastroenterol. 2008 Sep;42 Suppl 3 Pt 1:S144-7. doi: 10.1097/MCG.0b013e3181662c90. J Clin Gastroenterol. 2008. PMID: 18806708 Review.
-
Brosbøl-Ravnborg A, Hvas CL, Agnholt J, Dahlerup JF, Vind I, Till A, Rosenstiel P, Höllsberg P. Brosbøl-Ravnborg A, et al. Clin Exp Immunol. 2009 Mar;155(3):487-95. doi: 10.1111/j.1365-2249.2008.03850.x. Epub 2008 Dec 15. Clin Exp Immunol. 2009. PMID: 19094116 Free PMC article.
-
Han X, Uchida K, Jurickova I, Koch D, Willson T, Samson C, Bonkowski E, Trauernicht A, Kim MO, Tomer G, Dubinsky M, Plevy S, Kugathsan S, Trapnell BC, Denson LA. Han X, et al. Gastroenterology. 2009 Apr;136(4):1261-71, e1-3. doi: 10.1053/j.gastro.2008.12.046. Epub 2008 Dec 24. Gastroenterology. 2009. PMID: 19230854 Free PMC article.
-
Is Crohn's disease due to defective immunity?
Korzenik JR. Korzenik JR. Gut. 2007 Jan;56(1):2-5. doi: 10.1136/gut.2006.095588. Gut. 2007. PMID: 17172582 Free PMC article.
Cited by
-
New treatment options in the management of IBD - focus on colony stimulating factors.
Barahona-Garrido J, Yamamoto-Furusho JK. Barahona-Garrido J, et al. Biologics. 2008 Sep;2(3):501-4. doi: 10.2147/btt.s3543. Biologics. 2008. PMID: 19707380 Free PMC article.
-
The IL-1 family: regulators of immunity.
Sims JE, Smith DE. Sims JE, et al. Nat Rev Immunol. 2010 Feb;10(2):89-102. doi: 10.1038/nri2691. Epub 2010 Jan 18. Nat Rev Immunol. 2010. PMID: 20081871 Review.
-
Effect of fuzzy partitioning in Crohn's disease classification: a neuro-fuzzy-based approach.
Ahmed SS, Dey N, Ashour AS, Sifaki-Pistolla D, Bălas-Timar D, Balas VE, Tavares JM. Ahmed SS, et al. Med Biol Eng Comput. 2017 Jan;55(1):101-115. doi: 10.1007/s11517-016-1508-7. Epub 2016 Apr 22. Med Biol Eng Comput. 2017. PMID: 27106754
-
Innovative therapeutics for inflammatory bowel disease.
Yamamoto-Furusho JK. Yamamoto-Furusho JK. World J Gastroenterol. 2007 Apr 7;13(13):1893-6. doi: 10.3748/wjg.v13.i13.1893. World J Gastroenterol. 2007. PMID: 17461487 Free PMC article. Review.
-
[41-year old patient with obscure diarrhea].
Brünnler T, Bataille F, Hofstädter F, Birkenfeld G, Schölmerich J. Brünnler T, et al. Internist (Berl). 2009 Sep;50(9):1149-51, 1153-4. doi: 10.1007/s00108-009-2341-y. Internist (Berl). 2009. PMID: 19533073 German.
References
-
- Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem. 2001;276:4812–4818. - PubMed
-
- Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem. 2003;278:5509–5512. - PubMed
-
- Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003;278:8869–8872. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous